Peer-reviewed veterinary case report
Protamine zinc insulin controls high blood sugar in diabetic dogs
By Maggiore, A Della et al.·Published in Journal of veterinary internal medicine·2012·Veterinary Medical Teaching Hospital, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Efficacy of protamine zinc recombinant human insulin for controlling hyperglycemia in dogs with diabetes mellitus.
- Species:
- dog
Plain-English summary
A group of 17 dogs with diabetes that weren't well-controlled on their previous insulin were treated with a new type of insulin called recombinant human protamine zinc insulin (rhPZI) for 60 days. By the end of the study, most dogs showed significant improvements in their blood sugar levels, and symptoms like excessive urination and thirst improved for many of them. Their body weight remained stable or increased, indicating better overall health. While some dogs experienced low blood sugar as a side effect, rhPZI proved to be an effective alternative for managing diabetes in dogs.
People also search for: dog diabetes treatment · insulin for diabetic dogs · symptoms of dog diabetes · low blood sugar in dogs
Abstract
BACKGROUND: Alternative insulin preparations are needed when NPH insulin is ineffective in diabetic dogs. This study evaluated the efficacy of recombinant human protamine zinc insulin (rhPZI) for treating diabetic dogs. HYPOTHESIS: rhPZI is effective for treating diabetic dogs. ANIMALS: Six newly diagnosed and 11 insulin-treated diabetic dogs. METHODS: Prospective clinical trial. Dogs were treated with rhPZI for 60 days. Control of glycemia was assessed on days 7, 14, 30, and 60 by evaluation of history, physical examination, body weight, serum fructosamine concentration, and blood glucose concentrations measured before and 2, 4, 6, 8, and 10 hours after rhPZI administration. Adjustments in dosage of rhPZI were made as needed to control glycemia. RESULTS: rhPZI administration resulted in a significant decrease in 10-hour mean blood glucose (MBG(10h) ; 299 ± 115 versus 457 ± 38 mg/dL, X ± SD, P = .0003) and serum fructosamine (478 ± 83 versus 557 ± 104 μmol/L, P = .006) concentration at day 60, compared with day 1, respectively. By day 60, polyuria and polydipsia had improved in 14, body weight was stable or increased in 16, MBG(10h) had decreased in 16, and serum fructosamine concentration had decreased in 11 of 17 dogs, compared with day 1. Hypoglycemia (<80 mg/dL) was the only consistent adverse event. CONCLUSIONS AND CLINICAL RELEVANCE: rhPZI is effective in diabetic dogs and can be considered as an alternative treatment in diabetic dogs that are poorly controlled using other insulin preparations.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/22211582/